Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Stefania Morganti, M.D.

Title
Institution
Department
Address
Phone
Profile Picture

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Morganti S, Tolaney SM. Role of Immunotherapy in Early- and Late-Stage Triple-Negative Breast Cancer. Hematol Oncol Clin North Am. 2023 Feb; 37(1):133-150. PMID: 36435606.
    Citations:    Fields:    Translation:Humans
  2. Morganti S, Tolaney SM. Fluorouracil and dose-dense adjuvant chemotherapy in breast cancer: lessons learned from the 20-year-old GIM2 trial. Lancet Oncol. 2022 12; 23(12):1482-1484. PMID: 36370715.
    Citations:    Fields:    
  3. Schlam I, Tarantino P, Morganti S, Lynce F, Trapani D, Mayer EL, Garrido-Castro AC, Waks A, Tolaney SM. Emerging Targeted Therapies for Early Breast Cancer. Drugs. 2022 Sep; 82(14):1437-1451. PMID: 36207645.
    Citations:    Fields:    Translation:Humans
  4. Morganti S, Marra A, Crimini E, D'Amico P, Zagami P, Curigliano G. Refining risk stratification in HR-positive/HER2-negative early breast cancer: how to select patients for treatment escalation? Breast Cancer Res Treat. 2022 Apr; 192(3):465-484. PMID: 35124720.
    Citations:    Fields:    Translation:Humans
  5. de Sire A, Lippi L, Venetis K, Morganti S, Sajjadi E, Curci C, Ammendolia A, Criscitiello C, Fusco N, Invernizzi M. Efficacy of Antiresorptive Drugs on Bone Mineral Density in Post-Menopausal Women With Early Breast Cancer Receiving Adjuvant Aromatase Inhibitors: A Systematic Review of Randomized Controlled Trials. Front Oncol. 2021; 11:829875. PMID: 35127539; PMCID: PMC8814453.
    Citations: 7     
  6. Crimini E, Corti C, Repetto M, Giugliano F, Antonarelli G, Tarantino P, Zagami P, Morganti S, Nicolò E, Uliano J, Curigliano G. Systemic Treatment of Ductal Carcinoma In Situ of the Breast. Chirurgia (Bucur). 2021 12; 116(5 Suppl):S97-S104. PMID: 34967317.
    Citations:    Fields:    Translation:Humans
  7. Trillo Aliaga P, Trapani D, Sandoval JL, Crimini E, Antonarelli G, Vivanet G, Morganti S, Corti C, Tarantino P, Friedlaender A, Belli C, Minchella I, Locatelli M, Esposito A, Criscitiello C, Curigliano G. Safety of COVID-19 mRNA Vaccines in Patients with Cancer Enrolled in Early-Phase Clinical Trials. Cancers (Basel). 2021 Nov 20; 13(22). PMID: 34830983.
    Citations: 3     
  8. Repetto M, Crimini E, Giugliano F, Morganti S, Belli C, Curigliano G. Selective FGFR/FGF pathway inhibitors: inhibition strategies, clinical activities, resistance mutations, and future directions. Expert Rev Clin Pharmacol. 2021 Oct; 14(10):1233-1252. PMID: 34591728.
    Citations: 5     Fields:    Translation:HumansCells
  9. Fusco N, Ragazzi M, Sajjadi E, Venetis K, Piciotti R, Morganti S, Santandrea G, Fanelli GN, Despini L, Invernizzi M, Cerbelli B, Scatena C, Criscitiello C. Assessment of estrogen receptor low positive status in breast cancer: Implications for pathologists and oncologists. Histol Histopathol. 2021 Dec; 36(12):1235-1245. PMID: 34585734.
    Citations: 4     Fields:    Translation:Humans
  10. Criscitiello C, Marra A, Morganti S, Zagami P, Gandini S, Esposito A, Curigliano G. Clinical outcomes of patients with metastatic breast cancer enrolled in phase I clinical trials. Eur J Cancer. 2021 11; 157:40-49. PMID: 34474219.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  11. Venetis K, Piciotti R, Sajjadi E, Invernizzi M, Morganti S, Criscitiello C, Fusco N. Breast Cancer with Bone Metastasis: Molecular Insights and Clinical Management. Cells. 2021 06 02; 10(6). PMID: 34199522; PMCID: PMC8229615.
    Citations: 7     Fields:    Translation:Humans
  12. Tarantino P, Morganti S, Curigliano G. Targeting HER2 in breast cancer: new drugs and paradigms on the horizon. Explor Target Antitumor Ther. 2021; 2(2):139-155. PMID: 36046143; PMCID: PMC9400740.
    Citations: 1     
  13. Criscitiello C, Morganti S, Curigliano G. Antibody-drug conjugates in solid tumors: a look into novel targets. J Hematol Oncol. 2021 01 28; 14(1):20. PMID: 33509252; PMCID: PMC7844898.
    Citations: 28     Fields:    Translation:HumansAnimals
  14. Esposito A, Marra A, Bagnardi V, Frassoni S, Morganti S, Viale G, Zagami P, Varano GM, Buccimazza G, Orsi F, Venetis K, Mazzarella L, Viale G, Fusco N, Criscitiello C, Curigliano G. Body mass index, adiposity and tumour infiltrating lymphocytes as prognostic biomarkers in patients treated with immunotherapy: A multi-parametric analysis. Eur J Cancer. 2021 03; 145:197-209. PMID: 33493979.
    Citations: 3     Fields:    Translation:HumansCells
  15. Tarantino P, Morganti S, Uliano J, Giugliano F, Crimini E, Curigliano G. Margetuximab for the treatment of HER2-positive metastatic breast cancer. Expert Opin Biol Ther. 2021 02; 21(2):127-133. PMID: 33238772.
    Citations: 10     Fields:    Translation:Humans
  16. Morganti S, Curigliano G. Combinations using checkpoint blockade to overcome resistance. Ecancermedicalscience. 2020; 14:1148. PMID: 33574893; PMCID: PMC7864692.
    Citations: 5     
  17. Catania C, Spitaleri G, Del Signore E, Attili I, Radice D, Stati V, Gianoncelli L, Morganti S, de Marinis F. Fears and Perception of the Impact of COVID-19 on Patients With Lung Cancer: A Mono-Institutional Survey. Front Oncol. 2020; 10:584612. PMID: 33163413; PMCID: PMC7591454.
    Citations: 10     
  18. Criscitiello C, Marra A, Morganti S, Zagami P, Viale G, Esposito A, Curigliano G. Pretreatment Blood Parameters Predict Efficacy from Immunotherapy Agents in Early Phase Clinical Trials. Oncologist. 2020 11; 25(11):e1732-e1742. PMID: 32785940; PMCID: PMC7648370.
    Citations: 7     Fields:    Translation:HumansCells
  19. Conforti F, Pala L, Bagnardi V, Specchia C, Oriecuia C, Marra A, Zagami P, Morganti S, Tarantino P, Catania C, De Marinis F, Queirolo P, De Pas T. EGFR-TKI Plus Anti-Angiogenic Drugs in EGFR-Mutated Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Clinical Trials. JNCI Cancer Spectr. 2020 Dec; 4(6):pkaa064. PMID: 33344882; PMCID: PMC7737478.
    Citations: 2     Fields:    
  20. Passaro A, Attili I, Morganti S, Del Signore E, Gianoncelli L, Spitaleri G, Stati V, Catania C, Curigliano G, de Marinis F. Clinical features affecting survival in metastatic NSCLC treated with immunotherapy: A critical review of published data. Cancer Treat Rev. 2020 Sep; 89:102085. PMID: 32771858.
    Citations: 17     Fields:    Translation:Humans
  21. Tarantino P, Hamilton E, Tolaney SM, Cortes J, Morganti S, Ferraro E, Marra A, Viale G, Trapani D, Cardoso F, Penault-Llorca F, Viale G, Andrè F, Curigliano G. HER2-Low Breast Cancer: Pathological and Clinical Landscape. J Clin Oncol. 2020 06 10; 38(17):1951-1962. PMID: 32330069.
    Citations: 32     Fields:    Translation:Humans
  22. de Marinis F, Attili I, Morganti S, Stati V, Spitaleri G, Gianoncelli L, Del Signore E, Catania C, Rampinelli C, Omodeo Salè E, Spaggiari L, Mastrilli F, Passaro A. Results of Multilevel Containment Measures to Better Protect Lung Cancer Patients From COVID-19: The IEO Model. Front Oncol. 2020; 10:665. PMID: 32391282; PMCID: PMC7188943.
    Citations: 12     
  23. Tarantino P, Morganti S, Curigliano G. Biologic therapy for advanced breast cancer: recent advances and future directions. Expert Opin Biol Ther. 2020 09; 20(9):1009-1024. PMID: 32255704.
    Citations: 6     Fields:    Translation:Humans
  24. Mazzarella L, Morganti S, Marra A, Trapani D, Tini G, Pelicci P, Curigliano G. Master protocols in immuno-oncology: do novel drugs deserve novel designs? J Immunother Cancer. 2020 03; 8(1). PMID: 32238471.
    Citations: 5     Fields:    Translation:Humans
  25. Morganti S, Curigliano G. Editorial: Optimizing treatment strategy in early breast cancer: less is more, or more is better? Curr Opin Oncol. 2019 11; 31(6):469-471. PMID: 31464761.
    Citations: 1     Fields:    Translation:Humans
  26. Viale G, Morganti S, Ferraro E, Zagami P, Marra A, Curigliano G. What therapies are on the horizon for HER2 positive breast cancer? Expert Rev Anticancer Ther. 2019 09; 19(9):811-822. PMID: 31448640.
    Citations: 1     Fields:    Translation:HumansAnimals
  27. Tarantino P, Trapani D, Morganti S, Ferraro E, Viale G, D'Amico P, Duso BA, Curigliano G. Opportunities and challenges of implementing Pharmacogenomics in cancer drug development. Cancer Drug Resist. 2019; 2(1):43-52. PMID: 35582141; PMCID: PMC9019172.
    Citations: 1     
  28. Morganti S, Tarantino P, Ferraro E, D'Amico P, Duso BA, Curigliano G. Next Generation Sequencing (NGS): A Revolutionary Technology in Pharmacogenomics and Personalized Medicine in Cancer. Adv Exp Med Biol. 2019; 1168:9-30. PMID: 31713162.
    Citations: 41     Fields:    Translation:Humans
  29. Morganti S, Tarantino P, Ferraro E, D'Amico P, Viale G, Trapani D, Duso BA, Curigliano G. Complexity of genome sequencing and reporting: Next generation sequencing (NGS) technologies and implementation of precision medicine in real life. Crit Rev Oncol Hematol. 2019 Jan; 133:171-182. PMID: 30661654.
    Citations: 25     Fields:    Translation:Humans
  30. Quaquarini E, Sottotetti F, D'Ambrosio D, Malovini A, Morganti S, Marinello A, Pavesi L, Frascaroli M. Eribulin across multiple lines of chemotherapy: a retrospective study on quality of life and efficacy in metastatic breast cancer patients. Future Oncol. 2017 Apr; 13(11s):11-23. PMID: 28481185.
    Citations: 2     Fields:    Translation:Humans
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Morganti's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (89)
Explore
_
Co-Authors (6)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.